| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |